Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Long-term follow-up findings from STOMP and ORIOLE and analysis of genomic predictors of response
A comprehensive analysis highlights clinically relevant associations between genomic, transcriptomic features, immunologic profiles and treatment outcomes
Conversion from accelerated to regular approval was based on data from additional patients in the GEOMETRY mono-1 study
ARROW validates RET as a tissue-agnostic target
It adopted an extension of indication for the treatment of advanced RET-mutated medullary thyroid cancer
Evidence for efficacy is based on the results from the DESTINY-Breast04 study
Findings from the NCCTG N0147 Alliance study analysis
Findings from the MajesTEC-1 study
It is indicated as monotherapy in adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies
Findings from a pivotal single-arm phase II study
Findings from the CHRONOS study
Evidence for efficacy is based on the results from the ARASENS study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
